Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Pluristem Therapeutics (PSTI 3.96%) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Pluristem and see what CAPS investors are saying about the stock right now.
Pluristem facts
|
Headquarters (founded) |
Haifa, Israel (2001) |
|
Market Cap |
$198.6 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$757 thousand |
|
Management |
Chairman/CEO Zami Aberman |
|
Return on Equity (average, past 3 years) |
(73%) |
|
Cash/Debt |
$68.3 million / $0 |
|
Competitors |
Aastrom Biosciences |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 81% of the 15 All-Star members who have rated Pluristem believe the stock will underperform the S&P 500 going forward.
One of those Fools, biotech expert zzlangerhans, tapped yesterday's 7% stock price spike as particularly unsustainable:
Wow, Pluristem received approval in Germany! Approval to run a phase II trial there, that is. Pluristem CEO seems to be aware that issuing any PR with the word "approval" somewhere in it is good for a momentary 10% spike in share price. Someone should do a study to determine the correlation between these types of announcements and the lockup expiration dates for their dilutive financings.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
